Can MMR and Prevnar Be Given on the Same Day?
Yes, MMR and Prevnar (pneumococcal conjugate vaccine) can and should be administered on the same day. The Advisory Committee on Immunization Practices (ACIP) explicitly recommends concomitant administration of these vaccines, and studies demonstrate no safety concerns or interference with immune responses when given together. 1
Evidence-Based Recommendation
ACIP guidelines specifically state that MMR vaccines can be administered concomitantly with pneumococcal conjugate vaccines (including both PCV13-Prevnar and PCV7) at different anatomic sites. 1 This recommendation is supported by clinical trials showing no evidence of immune interference or increased adverse events. 1
Key Administration Requirements
Each vaccine must be injected at a separate anatomic site using different syringes. 1 Never mix vaccines in the same syringe unless specifically FDA-approved for such mixing. 2
Administer both vaccines during the same visit whenever possible. This approach maximizes the likelihood that children will be fully immunized on schedule and reduces missed opportunities for vaccination. 2
Document each vaccine's specific injection site, route, lot number, and date in the patient's permanent medical record. 3
Clinical Evidence Supporting Co-Administration
Immunogenicity Data
Multiple high-quality studies confirm that MMR and pneumococcal conjugate vaccines maintain full immunogenicity when given together:
A randomized trial of 694 children aged 12–15 months demonstrated that MMR administered with PCV7 produced seroconversion rates significantly greater than 90% for all antigens, with no clinically meaningful differences compared to sequential administration. 4
Concomitant administration of MMR with PCV7 and varicella vaccine showed antibody responses that were non-inferior to non-concomitant administration, with an acceptable safety profile. 5
Studies evaluating PHiD-CV (10-valent pneumococcal vaccine) with MMRV showed high booster responses to pneumococcal antigens without compromising safety or immunogenicity of either vaccine. 6
Safety Profile
Co-administration does not increase serious adverse events or create synergistic toxicity:
When MMR and PCV7 were given together, local and systemic reactions occurred at rates comparable to or lower than sequential administration. 4, 7
Fever patterns after concomitant administration showed two distinct peaks: days 0–2 (related to conjugate vaccines) and days 4–12 (related to MMR/MMRV), indicating independent rather than additive effects. 6
No statistically significant differences in individual adverse events were observed when hepatitis A vaccine was added to concomitant MMR and PCV-7 administration. 5
Timing Considerations
If MMR and Prevnar are not given on the same day, specific spacing rules apply:
Live vaccines (like MMR) that are not administered concomitantly must be separated by at least 4 weeks (28 days). 1, 8 However, Prevnar is an inactivated vaccine, so this rule does not apply to the MMR-Prevnar combination.
MMR can be given with inactivated vaccines like Prevnar without any required spacing interval. 2, 8
Common Pitfalls to Avoid
Do not defer vaccination because of concerns about simultaneous administration. The evidence overwhelmingly supports immediate co-administration, and delaying increases the risk of incomplete immunization. 3, 2
Do not require serologic testing before vaccinating (except when specifically indicated, such as pregnancy screening before MMR). This creates unnecessary barriers to timely immunization. 3
Do not postpone vaccination because the manufacturer of a previously administered dose is unknown. Vaccines from different manufacturers are interchangeable. 1, 3
Do not assume that giving multiple vaccines increases serious adverse events. Studies consistently show that concomitant administration is safe and does not produce additive toxicity. 4, 7, 5, 6
Practical Implementation
Children aged 12–15 months can safely receive up to seven injections in one visit (MMR, varicella, Hib, pneumococcal conjugate, DTaP, IPV, and hepatitis B), with ACIP data confirming the safety and feasibility of this practice. 2
The standard practice is to administer every indicated vaccine at every visit, thereby minimizing missed opportunities and maximizing on-time series completion. 2 This approach is especially critical when patient follow-up is uncertain or when rapid protection against multiple diseases is needed. 3, 2